MRUS MERUS B V

Merus to Present at Upcoming Investor Conferences

Merus to Present at Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences:

  • William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ET

  • Jefferies Global Healthcare Conference: Wednesday, June 4 at 3:10 p.m. ET

The webcasts of the presentations will be contemporaneously available on the of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus

is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit ,  and .

Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.





Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
 

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
EN
27/05/2025

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

 PRESS RELEASE
Free
MRUS MERUS B V

Merus to Present at Upcoming Investor Conferences

Merus to Present at Upcoming Investor Conferences UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ETJefferies Global Healthcare Conference: Wednesday, June 4 at ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge sowie Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, gab heute bekannt, dass Dr. Bill Lundberg, Präsident und Chief Executive Officer von Merus, an den folgenden Investorenkonferenzen teilnehmen wird: William Blair 45th Annual Growth Stock Conference: Dienstag, 3. Juni um 8:40 Uhr. CST/11:40 U...

May 27, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 27 mai 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), une société d’oncologie développant des anticorps multispécifiques de pleine longueur novateurs et des conjugués anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé ce jour la présence de son PDG Bill Lundberg, docteur en médecine, aux journées Investisseurs suivantes : 45e conférence annuelle William Blair sur les actions de croissance : mardi 3 juin à 8 h 40, heure centrale/9 h 40 heure de l’Es...

May 27, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
MRUS MERUS B V

Dynamic Top Pick List update Removing Merus

Last week, Merus announced solid interim Phase 2 data to be presented at the ASCO 2025 conference with its lead asset petosemtamab in combination with current standard of care Keytruda for first-line treatment of patients with head and neck cancer (PD-L1+ refractory/ metastatic (r/m) head and neck squamous cell carcinoma (HNSCC)), a cancer type that is notoriously hard to treat. The updated dataset contains more patients than last year's presentation and featured a 63% overall response rate (27/...

05/27/25 May 27, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeig...

Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeigen robuste Wirksamkeit und Dauerhaftigkeit bei der Erstlinienbehandlung von PD-L1-positivem r/m HNSCC - 63%ige Ansprechrate bei 24 auswertbaren Patienten beobachtet - 79%ige Gesamtüberlebensrate nach 12 Monaten; 9 Monate medianes progressionsfreies Überleben - Telefonkonferenz am Donnerstag, 22. Mai, um 17:30 Uhr (Eastern Time) UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, May 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Onkologieunternehmen, das innovative multispe...

May 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch